Chinese electric vehicle stocks had a relatively tough week, with Nio (NYSE: NIO) declining by about 5%, Xpeng (NYSE: XPEV) declining by about 11%, and Li Auto stock falling by about 15% over the last five trading days. In comparison, the S&P 500 gained almost 1.5% over the last week. The three stocks are also down by between 30% to 40% year-to-date. So what’s driving the recent sell-off? Firstly, investors are likely concerned that the global semiconductor shortage which is weighing in the automotive industry could increasingly impact Chinese EV players. Secondly, competition in the Chinese EV space is also mounting with large Chinese automakers, global auto majors, and upstarts betting big on electric vehicles in China. For example, China’s largest carmaker, Geely, is launching a premium electric car brand of its own. Ford also recently started taking orders for its all-electric Mustang Mach-E crossover vehicle in China. Even consumer electronics behemoth Xiaomi plans to invest about $10 billion in developing EVs. With the Shanghai Motor Show slated to begin on April 21, we are likely to see plenty of new EVs making their debuts in China. Although the EV market in China is sizable with around 1.3 million vehicles sold in 2020 and sales projected to grow by over 50% this year [1], higher competition will put pressure on the likes of Nio, Xpeng, and Li Auto.
U.S. listed Chinese electric vehicle stocks have declined considerably this year. Nio (NYSE: NIO) and Xpeng (NYSE: XPEV) are down by about 25% year-to-date, while Li Auto is down by close to 20%. In comparison, the broader NASDAQ index is up by 2% year-to-date. So what’s driving the decline? While high growth stocks, in general, have been impacted on account of rising interest rates, Chinese EV players are also being hurt by a couple of other factors. Firstly, competition is mounting. For instance, Tesla (NASDAQ: TSLA) recently started selling a locally made version of its Model Y, while China’s largest carmaker, Geely, is launching a premium electric car brand of its own. Secondly, the global chip shortage has started to hit Chinese EV majors. Nio will temporarily suspend the vehicle production activity at its manufacturing plant in Hefei for five working days starting from March 29 due to a lack of chips, and it’s likely that other players will also be impacted. Thirdly, U.S.-listed Chinese stocks are being weighed down by concerns that they could be de-listed from American exchanges, with the SEC beginning to review the financial audits of overseas companies.
Overall, listing related concerns aside, we think that Chinese EV stocks look like relatively good bets at current levels. The EV market in China is massive, with deliveries in 2020 standing at about 1.3 million units and sales projected to grow by over 50% this year. [1] Homegrown brands such as Nio, Li Auto, and Xpeng are better positioned to benefit, given their deeper knowledge of the local markets, favorable regulation, and unique innovations targeted at Chinese consumers. While these companies trade at high multiples, they have growth on their side, with all three companies on track to at least double revenue this year. See our analysis on Nio, Xpeng & Li Auto: How Do Chinese EV Stocks Compare? for an overview of the financial and valuation metrics of three major Chinese EV players.
[3/19/2021] Nio Stock A Buy?
Nio stock (NYSE: NIO) is down by almost 25% over the last month, trading at levels of around $42 per share. The stock is also down by about 34% from its all-time highs. So what’s driving the correction? Firstly, there has been a broader sell-off in high-growth stocks on account of rising interest rates. Secondly, competition in the luxury electric SUV space in China is increasing, with Tesla (NASDAQ: TSLA) commencing deliveries of a locally made version of its Model Y. Separately, the global shortage of semiconductors has also hurt automotive companies and investors are likely concerned that Nio could be impacted.
That said, we think Nio stock looks like a relatively good value at the moment. Although the stock still trades at a seemingly steep 12x projected 2021 revenues, Nio is growing very fast. Sales are projected to more than double this year and to grow by almost 65% in 2022, per consensus estimates. We think the company should continue to fare well despite growing competition. The EV market in China is massive, with sales in 2020 standing at about 1.3 million units and sales are projected to grow by over 50% this year. [1] Nio could have an edge in China, being a homegrown brand that offers unique innovations such as battery-as-a-service.
Chinese luxury electric vehicle maker Nio published a mixed set of Q4 2020 results on Monday. While the company’s loss per American Depositary Share was wider than expected at about -$0.14, revenues came in slightly ahead of expectations growing 46.7% sequentially to about $1.02 billion, driven by stronger deliveries of the ES8, ES6, and EC6 vehicles. Nio’s stock was down by about 5% in pre-market trading on Tuesday, likely due to the company’s lighter-than-expected guidance.
Nio expects to deliver between 20,000 and 20,500 vehicles in Q1 2021, marking an increase of about 17% at the midpoint from Q4 2020. [2] Considering that the company has already delivered 7,225 vehicles in January, sales over February and March are likely to be slightly weaker compared to January. Although this is possibly due to businesses remaining shut through the Lunar New year festival period that took place in early February, it should be noted that competition in the electric SUV space in China is also mounting. Tesla (NASDAQ: TSLA) recently started deliveries of a locally made version of its Model Y compact SUV. The vehicle is relatively competitively priced and could put pressure on luxury EV players such as Nio. Separately, the company has indicated that a shortage in semiconductors and batteries is likely to cut its production over Q2 2021 to 7,500 vehicles per month, down from 10,000.
[Updated 2/8/2021] Will Tesla’s Model Y Hurt Nio and Li Auto?
Tesla (NASDAQ: TSLA) is starting deliveries of a locally made version of its Model Y compact SUV in China. Will this impact high-flying Chinese electric vehicle makers Nio (NYSE: NIO) and Li Auto – who specializes in SUVs and have gained a lot of traction in the Chinese market in recent quarters. It looks like it. There were signs of a slowdown for both EV players in their January 2021 delivery figures. Deliveries of Li Auto’s Li-One SUV declined by 12% versus December to 5,379. Nio, too, saw delivery growth in January slow to 3% compared to December, when deliveries grew by around 30%. While these trends may not entirely be tied to Tesla’s entry into the crossover market, Tesla is expected to put pressure on both companies.
Tesla has been gaining ground in China. It sold over 23,000 locally made Model 3 vehicles in China in December – that’s more vehicles than the big three EV startups Nio, Li Auto, and Xpeng put together. Now the Model Y is arguably going to be more popular compared to the Model 3, considering Chinese customer’s preference for crossovers and SUVs. Although the Model Y is unlikely to qualify for China’s national subsidy for electric vehicles, unlike the Model 3 sedan, Tesla has also priced the vehicle competitively, starting at about RMB 339,900 ($52,500). That’s below the RMB 353,600 subsidized starting price for Nio’s EC6 SUV, and slightly ahead of the RMB 328,000 subsidized price for Li Auto’s SUVs. Tesla’s stronger global brand image and software features could make its vehicles much more attractive to Chinese customers. Tesla also has the scale to take on these companies in the SUV market. Its Shanghai plant which began operations in late 2019 is likely to produce as much as half a million vehicles this year. In comparison, Nio is looking to increase production capacity to about 150,000 units.
However, Nio and Li Auto do have some advantages. Charging infrastructure remains limited in China, hence Nio is betting big on modular batteries for its EVs that can be swapped out in a matter of minutes, helping to reduce range anxiety while providing batteries as a service (BaaS) under a subscription program. Similarly, Li’s focus is on vehicles that have a small gasoline engine that can generate additional electric power for the battery, reducing reliance on EV-charging infrastructure. These companies also have the backing of the Chinese government and big tech companies and this could prove an advantage not just from the perspective of understanding the market better, but also from a regulatory standpoint. For example, Nio’s backers include Tencent and Baidu. The company has also been bailed out by the Chinese government in the past.
[1/11/2021] Is Nio Worthy Of A $100 Billion Valuation?
Nio stock has rallied by over 15% over the last week, amid anticipation ahead of the company’s annual Nio day event that was held on Saturday. Nio’s market cap now stands at a whopping $93 billion- almost as much as General Motors and Ford combined. Does Nio warrant such a valuation? The company is certainly growing fast, with Revenue poised to double to about $5 billion in 2021 with deliveries growing fast (Nio delivered a record 7,000 cars in December). The addressable market is also growing quickly, considering that China – Nio’s home country – has set a target that 25% of car sales by 2025 must be new energy vehicles that are not purely gasoline-driven. That being said, is Nio building a competitive advantage to justify its current valuation and fend off rivals as the market gets more crowded?
Nio appears to be innovating in two key areas – namely battery technology and self-driving software, and this is a big part of the narrative driving the stock. Nio is betting big on modular batteries for its EVs that can be swapped out in a matter of minutes, helping to reduce range anxiety while providing batteries as a service (BaaS) under a subscription program. However, this is unlikely to give the company an edge, as other players can also easily replicate this. In fact, China’s EV policy encourages building in battery swapping. EVs priced above RMB300,000 (around $46,000) are granted subsidies only if they have a swapping option. Nio has also unveiled a denser battery pack with 150 kWh of capacity (up from 100kWh currently). This battery option will be available only in late 2022 – almost 2 years out – and it’s possible that other players could also have similar capacity batteries by then, working with mainstream battery cell suppliers such as CATL.
The company spent a good deal of time during its Nio Day event discussing the self-driving tech on its new sedan due in 2022 and a related monthly subscription program. The focus appeared to be more on the hardware such as high-resolution cameras, lidar sensors, and Nvidia processors – all of which are likely to be available to most other automakers. However, what really gives companies an edge in self-driving is the quality of software and the availability of vast amounts of data (miles driven) to improve algorithms. For perspective, Tesla has logged a total of 3 billion autonomous miles as of last April while Google’s Waymo logged about 20 million miles. It’s not clear how Nio will fare on these counts.
Overall, while Nio is certainly growing fast, building a brand that is becoming synonymous with luxury Chinese EVs, its valuation looks rich in our view, as we don’t see a sustainable competitive advantage yet. Nio now trades at about 18.6x consensus 2021 Revenues, which means that it is valued similarly to pricey Tesla, whose strong software and self-driving capabilities partly justify its valuation.
[12/15/2020] Why Has Nio Stock Been Trending Lower
Chinese premium Electric vehicle maker Nio has seen its stock decline by almost 20% over the last two weeks, falling to levels of around $41 per share despite posting a strong delivery number for the month of November with sales more than doubling year-over-year to 5,291 units. While part of the decline is likely due to some profit booking after an over 10x rally this year, Nio’s move to raise about $2.65 billion via a sizeable secondary share offering also hurt the stock. The offering was priced at about $39 per American depositary shares, a discount to the market price of about $42 as of Friday’s close. That said, this should be a net positive for the company in the long-run. The funding still comes at attractive valuations (Nio trades at a whopping 23x projected 2020 Revenue, ahead of Tesla) and dilution of existing shareholders is limited. Moreover, the funds should give the company a comfortable cash cushion, with the proceeds likely to be used to fund R&D for new vehicles and autonomous driving technology and to expand the company’s sales network.
[Updated 11/18/2020] Is Nio Overvalued?
Nio – the premium Chinese electric vehicle manufacturer – reported its Q3 2020 results on Tuesday, posting a smaller than expected quarterly loss, driven by record deliveries and higher margins. While Revenues rose by 22% sequentially to RMB 4.53 billion (about $667 million), gross margins expanded by about 480 basis points to 12.9% driven by lower material cost and better manufacturing efficiency. Nio continues to benefit from strong demand and incentives for EVs in China, guiding that it could deliver between 16,500 to 17,000 vehicles over Q4. This translates into a sequential growth of at least 35%. [3]
Despite the stronger-than-expected results and Q4 guidance, we think Nio stock looks overvalued. The stock is up by over 12x year-to-date and trades at about 27x projected 2020 Revenues. In comparison, Tesla – a more mature EV player, with solid software capabilities and growing exposure to China – trades at about 13x projected sales. While Nio’s growth rates are certainly higher than Tesla’s, it is also riskier considering the intense competition in the Chinese EV market, which has several hundreds of manufacturers.
[Updated 11/16/2020] As Nio Stock Continues To Surge, Are Investors Getting Ahead Of Themselves?
Nio – the premium Chinese EV manufacturer – has seen its stock soar a whopping 58% over the last month trading at about $45 per share, driven by strong delivery numbers for October and a conducive regulatory environment in China for EVs. After a 12x rally year to date, Nio’s market cap is now higher than General Motors. While Nio is no doubt growing quickly, with Revenue on track to double this year, the stock looks overvalued in our view for a couple of reasons. Firstly, there is a possibility that Tesla could give Nio a run for its money in its home turf, as it prepares to launch a locally made Model Y SUV, which reports indicate could be priced cheaper than Nio’s entry-level SUV ES6, which starts at $54k. In addition to a potentially lower price, Tesla’s stronger brand image and software features could make its vehicles much more attractive to customers. The company could also face challenges further scaling up production. For example, Nio recalled about 5,000 vehicles last year after reports of multiple fires. Nio is also very richly valued at about 26x projected 2020 Revenues, compared to Tesla which trades at about 12x. While Nio’s growth rates are certainly higher than Tesla’s, the risks are also higher given the intense competition in the Chinese EV space where there are over 400 manufacturers.
[11/3/2020] Strong October Deliveries Drive Chinese EV Stocks
The stock prices of major U.S. listed Chinese electric-vehicle manufacturers soared on Monday, as they reported strong deliveries for October. Nio – one of the largest EV startups in China – saw its stock soar by about 9%, as it reported that deliveries in October almost doubled year-over-year to 5,055 vehicles. Xpeng (NYSE: XPEV), another premium EV player saw its stock rise by about 7%, as it delivered about 3,040 vehicles through the month, marking an increase of about 230% from a year ago, driven primarily by sales of its P7 sedan which was launched earlier this year. However, deliveries were slightly lower month-over-month. Li Auto (NASDAQ: LI), a company that sells EVs that also have a small gasoline engine – said that it delivered 3,692 of its Li ONE SUVs in October, marking a month-over-month increase of about 5%. The company began production only late last year.
[10/30/2020] How Do Nio, Xpeng, and Li Auto Compare
The Chinese electric vehicle space is booming, with China-based manufacturers accounting for over 50% of global EV deliveries. Demand for EVs in China is likely to remain robust as the Chinese government wants about 25% of all new cars sold in the country to be electric by 2025, up from roughly 5% at present. [4] While Tesla is a leader in the Chinese luxury EV market driven by production at its new Shanghai facility, Nio, Xpeng (NYSE: XPEV), and Li Auto (NASDAQ: LI) – three relatively young U.S. listed Chinese electric vehicle players, have also been gaining traction. In our analysis Nio, Xpeng & Li Auto: How Do Chinese EV Stocks Compare? we compare the financial performance and valuation of the major U.S. listed Chinese electric vehicle players. Parts of the analysis are summarized below.
Overview Of Nio, Li Auto & Xpeng’s Business
Nio, which was founded in 2014, currently offers three premium electric SUVs, ES8, ES6, and EC6, which are priced starting at about $50k. The company is working on developing self-driving technology and also offers other unique innovations such as Battery as a Service (BaaS) – which allows customers to subscribe for car batteries, rather than paying for them upfront. While the company has scaled up production, it hasn’t come without challenges, as it recalled about 5,000 vehicles last year after reports of multiple fires.
Li Auto sells Extended-Range Electric Vehicles, which are essentially EVs that also have a small gasoline engine that can generate additional electric power for the battery. This reduces the need for EV-charging infrastructure, which is currently limited in China. The company’s hybrid strategy appears to be paying off – with its Li ONE SUV, which is priced at about $46,000 – ranking as the top-selling SUV in the new energy vehicle segment in China in September 2020. The new energy segment includes fuel cell, electric, and plug-in hybrid vehicles.
Xpeng produces and sells premium electric vehicles including the G3 SUV and the P7 four-door sedan, which are roughly positioned as rivals to Tesla’s Model Y SUV and Model 3 sedan, although they are more affordable, with the basic version of the G3 starting at about $22,000 post subsidies. The G3 SUV was among the top 3 Electric SUVs in terms of sales in China in 2019. While the company began production in late 2018, initially via a deal with an established automaker, it has started production at its own factory in the Guangdong province.
How Have The Deliveries, Revenues & Margins Trended
Nio delivered about 21k vehicles in 2019, up from about 11k vehicles in 2018. This compares to Xpeng which delivered about 13k vehicles in 2019 and Li Auto which delivered about 1k vehicles, considering that it began production only late last year. While Nio’s deliveries this year could approach about 40k units, Li Auto and Xpeng are likely to deliver around 25k vehicles with Li Auto seeing the highest growth. Over 2019, Nio’s Revenues stood at $1.1 billion, compared to about $40 million for Li Auto and $330 million for Xpeng. Nio’s Revenues are likely to grow 95% this year, while Xpeng’s Revenues are likely to grow by about 120%. All three companies remain deeply lossmaking as costs related to R&D and SG&A remain high relative to Revenues. Nio’s Net Margins stood at -195% in 2019, Li Auto’s margins stood at about -860% while Xpeng’s margins stood at -160%. However, margins are likely to improve sharply in 2020, as volumes pick up.
Revenue
Trefis
Valuation
Nio’s Market Cap stood at about $37 billion as of October 28, 2020, with its stock price rising by about 7x year-to-date due to surging investor interest in EV stocks. Li Auto and Xpeng, which were both listed in the U.S. around August as they looked to capitalize on surging valuations, have a market cap of about $15 billion and $14 billion, respectively. On a relative basis, Nio trades at about 15x projected 2020 Revenues, Li Auto trades at about 12x, while Xpeng trades at about 20x.
While valuations are certainly high, investors are likely betting that these companies will continue to grow in the domestic market, while eventually playing a larger role in the global EV space leveraging China’s relatively low-cost manufacturing, and the country’s ecosystem of battery and auto parts suppliers. Of the three companies, Nio might be the safer bet, considering its slightly longer track record, higher Revenues, and investments in technology such as battery swaps and self-driving. Li Auto also looks attractive considering its rapid growth – driven by the uptake of its hybrid powertrains – and relatively attractive valuation of about 12x 2020 Revenues.
Electric vehicles are the future of transportation, but picking the right EV stocks can be tricky. Investing in Electric Vehicle Component Supplier Stocks can be a good alternative to play the growth in the EV market.
TORONTO – Health Canada has authorized Moderna’s updated COVID-19 vaccine that protects against currently circulating variants of the virus.
The mRNA vaccine, called Spikevax, has been reformulated to target the KP.2 subvariant of Omicron.
It will replace the previous version of the vaccine that was released a year ago, which targeted the XBB.1.5 subvariant of Omicron.
Health Canada recently asked provinces and territories to get rid of their older COVID-19 vaccines to ensure the most current vaccine will be used during this fall’s respiratory virus season.
Health Canada is also reviewing two other updated COVID-19 vaccines but has not yet authorized them.
They are Pfizer’s Comirnaty, which is also an mRNA vaccine, as well as Novavax’s protein-based vaccine.
This report by The Canadian Press was first published Sept. 17, 2024.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
TORONTO – Sanniah Jabeen holds a sonogram of the unborn baby she lost after contracting listeria last December. Beneath, it says “love at first sight.”
Jabeen says she believes she and her baby were poisoned by a listeria outbreak linked to some plant-based milks and wants answers. An investigation continues into the recall declared July 8 of several Silk and Great Value plant-based beverages.
“I don’t even have the words. I’m still processing that,” Jabeen says of her loss. She was 18 weeks pregnant when she went into preterm labour.
The first infection linked to the recall was traced back to August 2023. One year later on Aug. 12, 2024, the Public Health Agency of Canada said three people had died and 20 were infected.
The number of cases is likely much higher, says Lawrence Goodridge, Canada Research Chair in foodborne pathogen dynamics at the University of Guelph: “For every person known, generally speaking, there’s typically 20 to 25 or maybe 30 people that are unknown.”
The case count has remained unchanged over the last month, but the Public Health Agency of Canada says it won’t declare the outbreak over until early October because of listeria’s 70-day incubation period and the reporting delays that accompany it.
Danone Canada’s head of communications said in an email Wednesday that the company is still investigating the “root cause” of the outbreak, which has been linked to a production line at a Pickering, Ont., packaging facility.
Pregnant people, adults over 60, and those with weakened immune systems are most at risk of becoming sick with severe listeriosis. If the infection spreads to an unborn baby, Health Canada says it can cause miscarriage, stillbirth, premature birth or life-threatening illness in a newborn.
The Canadian Press spoke to 10 people, from the parents of a toddler to an 89-year-old senior, who say they became sick with listeria after drinking from cartons of plant-based milk stamped with the recalled product code. Here’s a look at some of their experiences.
Sanniah Jabeen, 32, Toronto
Jabeen says she regularly drank Silk oat and almond milk in smoothies while pregnant, and began vomiting seven times a day and shivering at night in December 2023. She had “the worst headache of (her) life” when she went to the emergency room on Dec. 15.
“I just wasn’t functioning like a normal human being,” Jabeen says.
Told she was dehydrated, Jabeen was given fluids and a blood test and sent home. Four days later, she returned to hospital.
“They told me that since you’re 18 weeks, there’s nothing you can do to save your baby,” says Jabeen, who moved to Toronto from Pakistan five years ago.
Jabeen later learned she had listeriosis and an autopsy revealed her baby was infected, too.
“It broke my heart to read that report because I was just imagining my baby drinking poisoned amniotic fluid inside of me. The womb is a place where your baby is supposed to be the safest,” Jabeen said.
Jabeen’s case is likely not included in PHAC’s count. Jabeen says she was called by Health Canada and asked what dairy and fresh produce she ate – foods more commonly associated with listeria – but not asked about plant-based beverages.
She’s pregnant again, and is due in several months. At first, she was scared to eat, not knowing what caused the infection during her last pregnancy.
“Ever since I learned about the almond, oat milk situation, I’ve been feeling a bit better knowing that it wasn’t something that I did. It was something else that caused it. It wasn’t my fault,” Jabeen said.
She’s since joined a proposed class action lawsuit launched by LPC Avocates against the manufacturers and sellers of Silk and Great Value plant-based beverages. The lawsuit has not yet been certified by a judge.
Natalie Grant and her seven year-old daughter, Bowmanville, Ont.
Natalie Grant says she was in a hospital waiting room when she saw a television news report about the recall. She wondered if the dark chocolate almond milk her daughter drank daily was contaminated.
She had brought the girl to hospital because she was vomiting every half hour, constantly on the toilet with diarrhea, and had severe pain in her abdomen.
“I’m definitely thinking that this is a pretty solid chance that she’s got listeria at this point because I knew she had all the symptoms,” Grant says of seeing the news report.
Once her daughter could hold fluids, they went home and Grant cross-checked the recalled product code – 7825 – with the one on her carton. They matched.
“I called the emerg and I said I’m pretty confident she’s been exposed,” Grant said. She was told to return to the hospital if her daughter’s symptoms worsened. An hour and a half later, her fever spiked, the vomiting returned, her face flushed and her energy plummeted.
Grant says they were sent to a hospital in Ajax, Ont. and stayed two weeks while her daughter received antibiotics four times a day until she was discharged July 23.
“Knowing that my little one was just so affected and how it affected us as a family alone, there’s a bitterness left behind,” Grant said. She’s also joined the proposed class action.
Thelma Feldman, 89, Toronto
Thelma Feldman says she regularly taught yoga to friends in her condo building before getting sickened by listeria on July 2. Now, she has a walker and her body aches. She has headaches and digestive problems.
“I’m kind of depressed,” she says.
“It’s caused me a lot of physical and emotional pain.”
Much of the early days of her illness are a blur. She knows she boarded an ambulance with profuse diarrhea on July 2 and spent five days at North York General Hospital. Afterwards, she remembers Health Canada officials entering her apartment and removing Silk almond milk from her fridge, and volunteers from a community organization giving her sponge baths.
“At my age, 89, I’m not a kid anymore and healing takes longer,” Feldman says.
“I don’t even feel like being with people. I just sit at home.”
Jasmine Jiles and three-year-old Max, Kahnawake Mohawk Territory, Que.
Jasmine Jiles says her three-year-old son Max came down with flu-like symptoms and cradled his ears in what she interpreted as a sign of pain, like the one pounding in her own head, around early July.
When Jiles heard about the recall soon after, she called Danone Canada, the plant-based milk manufacturer, to find out if their Silk coconut milk was in the contaminated batch. It was, she says.
“My son is very small, he’s very young, so I asked what we do in terms of overall monitoring and she said someone from the company would get in touch within 24 to 48 hours,” Jiles says from a First Nations reserve near Montreal.
“I never got a call back. I never got an email”
At home, her son’s fever broke after three days, but gas pains stuck with him, she says. It took a couple weeks for him to get back to normal.
“In hindsight, I should have taken him (to the hospital) but we just tried to see if we could nurse him at home because wait times are pretty extreme,” Jiles says, “and I don’t have child care at the moment.”
Joseph Desmond, 50, Sydney, N.S.
Joseph Desmond says he suffered a seizure and fell off his sofa on July 9. He went to the emergency room, where they ran an electroencephalogram (EEG) test, and then returned home. Within hours, he had a second seizure and went back to hospital.
His third seizure happened the next morning while walking to the nurse’s station.
In severe cases of listeriosis, bacteria can spread to the central nervous system and cause seizures, according to Health Canada.
“The last two months have really been a nightmare,” says Desmond, who has joined the proposed lawsuit.
When he returned home from the hospital, his daughter took a carton of Silk dark chocolate almond milk out of the fridge and asked if he had heard about the recall. By that point, Desmond says he was on his second two-litre carton after finishing the first in June.
“It was pretty scary. Terrifying. I honestly thought I was going to die.”
Cheryl McCombe, 63, Haliburton, Ont.
The morning after suffering a second episode of vomiting, feverish sweats and diarrhea in the middle of the night in early July, Cheryl McCombe scrolled through the news on her phone and came across the recall.
A few years earlier, McCombe says she started drinking plant-based milks because it seemed like a healthier choice to splash in her morning coffee. On June 30, she bought two cartons of Silk cashew almond milk.
“It was on the (recall) list. I thought, ‘Oh my God, I got listeria,’” McCombe says. She called her doctor’s office and visited an urgent care clinic hoping to get tested and confirm her suspicion, but she says, “I was basically shut down at the door.”
Public Health Ontario does not recommend listeria testing for infected individuals with mild symptoms unless they are at risk of developing severe illness, such as people who are immunocompromised, elderly, pregnant or newborn.
“No wonder they couldn’t connect the dots,” she adds, referencing that it took close to a year for public health officials to find the source of the outbreak.
“I am a woman in my 60s and sometimes these signs are of, you know, when you’re vomiting and things like that, it can be a sign in women of a bigger issue,” McCombe says. She was seeking confirmation that wasn’t the case.
Disappointed, with her stomach still feeling off, she says she decided to boost her gut health with probiotics. After a couple weeks she started to feel like herself.
But since then, McCombe says, “I’m back on Kawartha Dairy cream in my coffee.”
This report by The Canadian Press was first published Sept. 16, 2024.
Canadian Press health coverage receives support through a partnership with the Canadian Medical Association. CP is solely responsible for this content.
VANCOUVER – Mayors and other leaders from several British Columbia communities say the provincial and federal governments need to take “immediate action” to tackle mental health and public safety issues that have reached crisis levels.
Vancouver Mayor Ken Sim says it’s become “abundantly clear” that mental health and addiction issues and public safety have caused crises that are “gripping” Vancouver, and he and other politicians, First Nations leaders and law enforcement officials are pleading for federal and provincial help.
In a letter to Prime Minister Justin Trudeau and Premier David Eby, mayors say there are “three critical fronts” that require action including “mandatory care” for people with severe mental health and addiction issues.
The letter says senior governments also need to bring in “meaningful bail reform” for repeat offenders, and the federal government must improve policing at Metro Vancouver ports to stop illicit drugs from coming in and stolen vehicles from being exported.
Sim says the “current system” has failed British Columbians, and the number of people dealing with severe mental health and addiction issues due to lack of proper care has “reached a critical point.”
Vancouver Police Chief Adam Palmer says repeat violent offenders are too often released on bail due to a “revolving door of justice,” and a new approach is needed to deal with mentally ill people who “pose a serious and immediate danger to themselves and others.”
This report by The Canadian Press was first published Sept. 16, 2024
